Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database

OBJECTIVE: Three oral anticoagulants have reported study results for stroke prevention in patients with atrial fibrillation (AF) (dabigatran etexilate, rivaroxaban and apixaban); all demonstrated superiority or non-inferiority compared with warfarin (RE-LY, ARISTOTLE and ROCKET-AF). This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sally, Monz, Brigitta U, Clemens, Andreas, Brueckmann, Martina, Lip, Gregory Y H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2012
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533028/
https://www.ncbi.nlm.nih.gov/pubmed/23242482
http://dx.doi.org/10.1136/bmjopen-2012-001768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533028/
https://www.ncbi.nlm.nih.gov/pubmed/23242482
http://dx.doi.org/10.1136/bmjopen-2012-001768

Ejemplares similares